Estimation of Galectin-3, cyclooxygenase-2 and thyroid hormones in papillary thyroid carcinoma

Abstract

Thyroid cancer is one of the most critical endocrine cancers, and ismore common in women than in men, but the associated causes of these differences are not fully understood. Serum biomarkers were tested in Iraqi thyroid cancer patients as part of this study's objective. Galectin-3, cyclooxygenase-2 (COX-2), thyroid stimulating hormone (TSH), Thyroxin (T4) and triiodothyronine (T3), could be useful in the identification, screening, diagnosis and follow-up of thyroid cancer patients. 60 thyroid cancer patients' anthrobiological features were found to have considerable abnormalities in all traits. The results showed a significant increase (p < 0.05) in the mean value of Triiodothyronine (T3) (2.418±1.153,0.664±1.206) Thyroxine (T4) (10.380±3.483,6.967±2.221) Thyroid-stimulating hormone (TSH) (7.466±16.119,1.286±1.168) COX2(1.828±0.725,2.663±0.985) Galectin by Elisa (145.243±180.9,46.441±27.874) levels in patients compared to the control group. Compared to the control group, the estimates of variation % results for patients are more exact. ‎(ROC)(AUC) was measured to evaluate sensitivity and specificity. The higher the sensitivity, the more likely it is that the disease carriers will be classified correctly, while specificity cares about healthy people. T3 and Galectin-3 have high sensitivity. Pearson's correlation coefficient between all measured parameters shows there is no correlation significance.